EN
EN
About TCRCure
Research and Development
Product and Cinical trial
News and Media
Become a global leader of cellular immunotherapy.
Become a global leader of cellular immunotherapy.
Become a global leader of cellular immunotherapy.
More
We strive to make patients-driven cellular immunotherapy innovation, to transform cancer into a manageable condition — and ultimately cure it.
We strive to make patients-driven cellular immunotherapy innovation, to transform cancer into a manageable condition — and ultimately cure it.
We strive to make patients-driven cellular immunotherapy innovation, to transform cancer into a manageable condition — and ultimately cure it.
More
ABOUT US

We are a clinical stage immune cell therapy biopharmaceutical company in China focused on the innovation, development and clinical translation of cellular immunotherapies mainly for solid tumors. Leveraging multiple proprietary cell engineering platforms, we are currently advancing eight pipelines, investigating the emerging field of immune cell therapies across multiple cancer types.


View More
Technology
ASPIRET Platform
A next-generation T cell therapy platform that redirects the TCR/CD3 complex to overcome key limitations of conventional CAR-T and TCR-T therapies, delivering robust, sustained, and safer immune responses against solid tumors.
More
ARMORS Platform
An advanced cell armoring platform that enhances ACT therapies by equipping them to overcome TME barriers and heterogeneity, improving safety, infiltration, and persistence in solid tumors.
More
TRUST Platform
An AI-powered high-throughput platform that rapidly discovers therapeutic TCRs by integrating single-cell transcriptomic and functional analysis, significantly cutting time and cost in TCR-based drug development.
More
Industrial-Grade Clinical Vector Production Platform
Industrial-scale clinical-grade vector and engineered immune cell production serves as the foundation for clinical development capabilities in immune cell therapy.
More
ASPIRE-T
A next-generation T cell therapy platform that redirects the TCR/CD3 complex to overcome key limitations of conventional CAR-T and TCR-T therapies, delivering robust, sustained, and safer immune responses against solid tumors.
More
Breaking boundaries: Current progress of anticancer NK cell-based drug development
News
Breaking boundaries: Current progress of anticancer NK cell-based drug development
2023-01-03
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy
News
Tumor-induced erythroid precursor-differentiated myeloid cells mediate immunosuppression and curtail anti-PD-1/PD-L1 treatment efficacy
2022-06-14
Core Team
Become a global leader of cellular immunotherapy
Our team brings together top-tier scientists and experienced executives with deep expertise in oncology and cell therapy. Our team consists of industry pioneers in cellular immunotherapy, with a proven track record in developing, manufacturing and launching successful cancer immunotherapy products. We believe we are united by a mission: to transform cancer into a manageable condition — and ultimately, to cure it.
View More

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
About TCRCure
Research and Development
Product and Cinical trial
News and Media

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer